Izokibep, a Unique IL-17A Inhibitor, Improves Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis up to Week 46 Phase 2 RCT Results

被引：0
|
作者：
Taylor, Peter C. [1 ]
de Vlam, Kurt [2 ]
Mease, Philip J. [3 ,4 ]
Peloso, Paul M. [5 ]
Wetzel, Dieter [6 ]
Lertratanakul, Apinya [7 ]
Brun, Nikolai [8 ]
Wiens, Brian [9 ]
Brandt-Juergens, Jan
Drescher, Edit [10 ]
Dokoupilova, Eva [11 ,12 ]
Rowinska-Osuch, Anna [13 ]
Martin, Nadia Abdel-Kader [14 ]
Behrens, Frank [15 ,16 ]
机构：
[1] Univ Oxford, Nuffield Dept Orthoped Rheumatol & Musculoskeleta, Oxford, England
[2] Univ Hosp Leuven, Leuven, Belgium
[3] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA
[4] Univ Washington, Sch Med, Seattle, WA USA
[5] ACELYRIN INC, Naples, FL USA
[6] Toclinco GmbH, Freiburg, Germany
[7] ACELYRIN, Chicago, IL USA
[8] Affibody AB, Solna, Sweden
[9] ACELYRIN Inc, Half Moon Bay, CA USA
[10] Csolnoky Ferenc Hosp, Vital Med Ctr Private Clin, Veszprem, Hungary
[11] Masaryk Univ, Fac Pharm, Dept Pharmaceut Technol, Brno, Czech Republic
[12] MED PLUS Sro, Brno, Czech Republic
[13] ETG Warszawa, Warsaw, Poland
[14] Hosp Quironsalud Infanta Luisa, Seville, Spain
[15] Goethe Univ, Div Rheumatol, Univ Hosp, Frankfurt, Germany
[16] Fraunhofer Inst Translat Med & Pharmacol, Frankfurt, Germany
来源：
ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1431
引用
收藏
页码：2814 / 2816
页数：3
相关论文
共 50 条
  • [21] Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks
    Kavanaugh, A.
    Marzo-Ortega, H.
    Vender, R.
    Wei, C. -C.
    Birt, J.
    Adams, D. H.
    Benichou, O.
    Lin, C. -Y.
    Nash, P.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (04) : 566 - 574
  • [22] Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial
    Strand, Vibeke
    Kosinski, Mark
    Chen, Chieh-I
    Joseph, George
    Rendas-Baum, Regina
    Graham, Neil M. H.
    van Hoogstraten, Hubert
    Bayliss, Martha
    Fan, Chunpeng
    Huizinga, Tom
    Genovese, Mark C.
    ARTHRITIS RESEARCH & THERAPY, 2016, 18
  • [23] IXEKIZUMAB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR-INHIBITORS
    Kavanaugh, A.
    Vender, R.
    Birt, J.
    Adams, D. H.
    Benichou, O.
    Lin, C. -Y.
    Nash, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 941 - 941
  • [24] DISEASE ACTIVITY OUTCOMES WITH THE IL-17A-AND IL-17F-INHIBITING NANOBODY SONELOKIMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (PSA): WEEK 12 RESULTS FROM THE PHASE 2 ARGO TRIAL
    Schett, G.
    McInnes, I. B.
    Mease, P. J.
    Kavanaugh, A.
    Eder, L.
    Kivitz, A. J.
    Godwood, A.
    Attar, N.
    Cullen, E.
    Reich, K.
    Coates, L. C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2024, 42 (09) : 20 - 21
  • [25] Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial
    Vibeke Strand
    Mark Kosinski
    Chieh-I Chen
    George Joseph
    Regina Rendas-Baum
    Neil M. H. Graham
    Hubert van Hoogstraten
    Martha Bayliss
    Chunpeng Fan
    Tom Huizinga
    Mark C. Genovese
    Arthritis Research & Therapy, 18
  • [26] Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials
    Wallenstein, G. V.
    Kanik, K. S.
    Wilkinson, B.
    Cohen, S.
    Cutolo, M.
    Fleischmann, R.
    Genovese, M. C.
    Gomez Reino, J.
    Gruben, D.
    Kremer, J.
    Krishnaswami, S.
    Lee, E. B.
    Pascual-Ramos, V.
    Strand, V.
    Zwillich, S. H.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (03) : 430 - 442
  • [27] Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2
    Ostor, Andrew J. K.
    Soliman, Ahmed M.
    Papp, Kim A.
    Padilla, Byron
    Wang, Zailong
    Eldred, Ann
    de Vlam, Kurt
    Kivitz, Alan
    RMD OPEN, 2022, 8 (02):
  • [28] Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24-Week Patient-Reported Outcome Results of a Phase III, Multicenter Study
    Gladman, D.
    Fleischmann, R.
    Coteur, G.
    Woltering, F.
    Mease, P. J.
    ARTHRITIS CARE & RESEARCH, 2014, 66 (07) : 1085 - 1092
  • [29] TOFACITINIB IMPROVES DISEASE ACTIVITY AND PATIENT-REPORTED OUTCOMES (PROS) IN PATIENTS (PTS) WITH ACTIVE PSORIATIC ARTHRITIS (PSA) IN REAL CLINICAL PRACTICE.
    Korotaeva, T.
    Vorobyova, L.
    Loginova, E.
    Gubar, E.
    Korsakova, Y.
    Glukhova, S.
    Karpova, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1725 - 1725
  • [30] Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies
    Ana-Maria Orbai
    Philip J. Mease
    Philip S. Helliwell
    Oliver FitzGerald
    Dona L. Fleishaker
    Rajiv Mundayat
    Pamela Young
    BMC Rheumatology, 6
12345